Patrick Ross

Patrick Ross

Auto-generated profile, based on publicly available information

Patrick Ross

Department of Medicinal Chemistry University of Kansas Lawrence Kansas USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
PRPatrick Ross
Patrick Ross
HFHijab Fatima
Hijab Fatima
DLDaniel P Leaman
Daniel P Leaman
JMJessica Matthias
Jessica Matthias
KSKathryn Spencer
Kathryn Spencer
CMCharles Daniel Murin
Charles Daniel Murin
Natural Killer (NK) cells utilize effector functions, including antibody-dependent cellular cytotoxicity (ADCC), for the clearance of viral infection and cellular malignancies. NK cell ADCC is mediated by Fc γ RIIIa (CD16a) binding to the fragment crystallizable (Fc) region of immunoglobulin G (IgG) within immune complexes on a target cell surface. While antibody-induced clustering of CD16a is thought to drive ADCC, the molecular basis for this activity has not been fully described. Here we use MINFLUX nanoscopy to map the spatial distribution of stoichiometrically labeled CD16a across the NK cell membrane, revealing the presence of pairs of CD16a molecules with intra-doublet distance of approximately 17 nm. NK cells activated on supported lipid bilayers by Trastuzumab results in an increase of synaptic regions with greater CD16a density. Our results provide the highest spatial resolution yet described for CD16a imaging, offering new insight into how CD16a organization within the immune synapse could influence ADCC activity. MINFLUX holds great promise to further unravel the molecular details driving CD16a-based activation of NK cells.

18 September 2026 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
PDF file
MRMatthew C. Russolillo
Matthew C. Russolillo
WNWariya Nirachonkul
Wariya Nirachonkul
NRNora Ross
Nora Ross
RHRahul M. Hedau
Rahul M. Hedau
ZCZachary Clark
Zachary Clark
Mark P. FarrellMark P. Farrell
Mark P. Farrell
Weak and transient carbohydrate–protein interactions hinder the detection of carbohydrate‐binding proteins (CBPs) in native settings. Here, we introduce carbohydrate‐directed labeling probes (CDLPs), modular ligand‐directed covalent probes composed of a glycan ligand, an acyl‐transfer electrophile, and a distal azide handle. Glycan binding positions the electrophile for proximity‐enhanced, glycan‐releasing acyl transfer, leaving an azide‐bearing acyl tag on the protein. Benchmark CDLPs capture carbohydrate–protein interactions with monovalent K D values extending into the millimolar range. In Daudi B cells, a 6′‐sialyllactose CDLP preferentially captures CD22 (Siglec‐2), demonstrating glycan‐dependent labeling in live cells. Quantitative chemoproteomics using 6′‐sialyllactose‐ and lactose‐CDLPs yields complementary competition‐sensitive CDLP‐capture profiles (6′SL‐CDLP: 95; Lac‐CDLP: 113; 21 shared), including canonical CBPs, glycan‐processing proteins, and candidate proteins lacking prior glycan‐related annotations. CDLPs provide an accessible, UV‐independent route to durable covalent readouts for targeted validation and proteome‐scale candidate discovery.

14 June 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
KAKyle Apley
Kyle Apley
AGAmber Griffith
Amber Griffith
GDGrant M. Downes
Grant M. Downes
PRPatrick Ross
Patrick Ross
Mark P. FarrellMark P. Farrell
Mark P. Farrell
CBCory Berkland
Cory Berkland
Pancreatic islet-reactive B lymphocytes promote Type 1 diabetes (T1D) by presenting antigen to islet-destructive T cells. Teplizumab, an anti-CD3 monoclonal, delays T1D onset in patients at risk, but additional therapies are needed to prevent disease entirely. Therefore, bifunctional molecules were designed to selectively inhibit T1D-promoting anti-insulin B cells by conjugating a ligand for the B cell inhibitory receptor CD22 (i.e., CD22L) to insulin, which permit these molecules to concomitantly bind to anti-insulin B cell receptors (BCRs) and CD22. Two prototypes were synthesized: 2:2 insulin-CD22L conjugate on a 4-arm PEG backbone, and 1:1 insulin-CD22L direct conjugate. Transgenic mice (125TgSD) expressing anti-insulin BCRs provided cells for in vitro testing. Cells were cultured with constructs for three days then assessed by flow cytometry. Duplicate wells with anti-CD40 simulated T cell help. Surprisingly, a 2-insulin 4-arm PEG control caused robust proliferation and activation-induced CD86 upregulation. Anti-CD40 further boosted these effects. This was unexpected, as soluble insulin alone has no effect, and may indicate that BCR-crosslinking occurs when antigens are tethered by the PEG backbone. Addition of CD22L via the 2:2 insulin-CD22L conjugate restored B cell properties to that of controls without additional beneficial effect. In contrast, the 1:1 insulin-CD22L direct conjugate significantly reduced anti-insulin B cell proliferation in the presence of anti-CD40. CD22L alone had no effect, and the constructs did not affect WT B cells. Thus, high valency constructs activate anti-insulin B cells, while low-valency antigen-CD22L conjugates co-ligate BCR and CD22, reducing B cell activation in response to simulated T cell help and reducing pathogenic B cell numbers without harming normal cells. Thus, the insulin-CD22L direct conjugate is a promising candidate for preclinical trials to prevent T1D without inducing immunodeficiency

18 September 2026 in Angewandte Chemie
Verified
Journal Article
Open access
PDF file
MRMatthew C. Russolillo
Matthew C. Russolillo
WNWariya Nirachonkul
Wariya Nirachonkul
NRNora Ross
Nora Ross
RHRahul M. Hedau
Rahul M. Hedau
ZCZachary Clark
Zachary Clark
Mark P. FarrellMark P. Farrell
Mark P. Farrell
Weak and transient carbohydrate–protein interactions hinder the detection of carbohydrate‐binding proteins (CBPs) in native settings. Here, we introduce carbohydrate‐directed labeling probes (CDLPs), modular ligand‐directed covalent probes composed of a glycan ligand, an acyl‐transfer electrophile, and a distal azide handle. Glycan binding positions the electrophile for proximity‐enhanced, glycan‐releasing acyl transfer, leaving an azide‐bearing acyl tag on the protein. Benchmark CDLPs capture carbohydrate–protein interactions with monovalent K D values extending into the millimolar range. In Daudi B cells, a 6′‐sialyllactose CDLP preferentially captures CD22 (Siglec‐2), demonstrating glycan‐dependent labeling in live cells. Quantitative chemoproteomics using 6′‐sialyllactose‐ and lactose‐CDLPs yields complementary competition‐sensitive CDLP‐capture profiles (6′SL‐CDLP: 95; Lac‐CDLP: 113; 21 shared), including canonical CBPs, glycan‐processing proteins, and candidate proteins lacking prior glycan‐related annotations. CDLPs provide an accessible, UV‐independent route to durable covalent readouts for targeted validation and proteome‐scale candidate discovery.